表紙：アンドロゲン遮断療法の市場規模、シェア、成長分析、ADTタイプ別、適応症別、投与経路別、患者属性別、流通チャネル別、地域別 - 産業予測、2025年～2032年

市場調査レポート

商品コード

1775653

アンドロゲン遮断療法の市場規模、シェア、成長分析、ADTタイプ別、適応症別、投与経路別、患者属性別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Androgen Deprivation Therapy Market Size, Share, and Growth Analysis, By Type of ADT (GnRH Analogues, Anti-androgens), By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年07月18日
発行: SkyQuest
ページ情報: 英文 189 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 786,626円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 920,204円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,053,782円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.42円

全表示
概要
目次

概要

サンプル依頼リストに入れる

アンドロゲン遮断療法の世界市場規模は2023年に67億米ドルと評価され、2024年の70億8,000万米ドルから2032年には109億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.6％で成長する見通しです。

世界のアンドロゲン遮断療法市場は、前立腺がんの罹患率の増加とホルモン感受性腫瘍に対する意識の高まりによって成長を遂げています。ドラッグデリバリーの革新、特に長時間作用型の注射薬や経口薬が治療の選択肢を増やしています。高齢化社会における診断率の向上、有利な償還政策、デジタルモニタリングシステムの使用により、これらの治療法に対する患者のアクセスはさらに拡大しています。とはいえ、発展途上諸国では、潜在的な心臓への副作用や高コストといった課題が大きな障壁となっています。今後の主な動向としては、最適化された治療のためのAIの統合、バイオシミラーの台頭、リアルタイムのホルモン抑制モニタリングの進歩などがあり、これらすべてが長期的な臨床効果と市場の商業化を形成する態勢を整えています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Ferring B V
AstraZeneca
Bayer AG
Astellas Pharma Inc
Johnson & Johnson
Foresee Pharmaceuticals Co Ltd
Viatris
Verity Pharmaceuticals Inc
AbbVie Inc
Bristol-Myers Squibb Company
Tolmar Pharmaceuticals Inc

結論と提言

Product Code: SQMIG35I2405

Global Androgen Deprivation Therapy Market size was valued at USD 6.7 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 10.94 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The Global Androgen Deprivation Therapy market is experiencing growth driven by the increasing incidence of prostate cancer and heightened awareness of hormone-sensitive tumors. Innovations in drug delivery, particularly long-acting injectables and oral medications, are enhancing treatment options. Improved diagnosis rates among aging populations, favorable reimbursement policies, and the use of digital monitoring systems are further expanding patient access to these therapies. Nevertheless, challenges such as potential cardiac side effects and high costs in developing countries pose significant barriers. Key future trends include the integration of AI for optimized therapies, the rise of biosimilars, and advancements in real-time hormone suppression monitoring, all of which are poised to shape long-term clinical efficacy and market commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Androgen Deprivation Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Androgen Deprivation Therapy Market Segments Analysis

Global Androgen Deprivation Therapy Market is segmented by Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Type of ADT, the market is segmented into GnRH Analogues and Anti-androgens. Based on Indication, the market is segmented into Localized Prostate Cancer and Advanced Prostate Cancer. Based on Route of Administration, the market is segmented into Intramuscular and Subcutaneous. Based on Patient Demographics, the market is segmented into Men aged 40-60, Men aged 61-75 and Men above 75. Based on Distribution Channel, the market is segmented into Hospitals, Specialized Cancer Clinics, Online Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Androgen Deprivation Therapy Market

The increasing global prevalence of prostate cancer among older men is significantly driving the demand for androgen deprivation therapy. This treatment remains the preferred approach for managing hormone-sensitive prostate cancer, particularly in cases of advanced or metastatic disease. Additionally, initiatives aimed at enhancing screening programs and raising awareness around early detection contribute to the growing volumes of patients seeking this therapy. As more individuals recognize the importance of timely diagnosis and intervention, the market for androgen deprivation therapy is poised for continued growth in response to these escalating needs within the healthcare landscape.

Restraints in the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market faces significant restraints due to the high costs associated with innovative treatments, including new oral blockers and long-acting injectables. These expenses often exceed the capabilities of standard insurance and public health budgets, particularly in developing nations. This creates a major barrier to affordability, compounded by inadequate reimbursement for patients and a lack of coordination within healthcare systems. As a result, many individuals in these regions may struggle to access necessary therapies, limiting the overall growth and potential of the market. Addressing these financial and systemic challenges is essential for improving patient access to effective treatments.

Market Trends of the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy (ADT) market is witnessing a significant shift toward new-generation oral hormone blockers, driven by patient preference for convenience and reduced clinic visits. By early 2024, oral luteinizing hormone-releasing hormone (LHRH) antagonists and antiandrogens have become first-line outpatient treatment options for prostate cancer, aligning with a broader trend toward decentralized care. This transition from injectable therapies to oral administration not only enhances patient compliance but also transforms treatment paradigms, indicating a robust growth trajectory for the ADT market. As healthcare systems adapt to these innovations, the demand for oral therapies is poised to accelerate.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Androgen Deprivation Therapy Market Size by Type of ADT & CAGR (2025-2032)

Market Overview
GnRH Analogues
Anti-androgens

Global Androgen Deprivation Therapy Market Size by Indication & CAGR (2025-2032)

Market Overview
Localized Prostate Cancer
Advanced Prostate Cancer

Global Androgen Deprivation Therapy Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intramuscular
Subcutaneous

Global Androgen Deprivation Therapy Market Size by Patient Demographics & CAGR (2025-2032)

Market Overview
Men aged 40-60
Men aged 61-75
Men above 75

Global Androgen Deprivation Therapy Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospitals
Specialized Cancer Clinics
Online Pharmacies
Retail Pharmacies

Global Androgen Deprivation Therapy Market Size & CAGR (2025-2032)

North America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
- US
- Canada
Europe (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Ferring B V
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foresee Pharmaceuticals Co Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Verity Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tolmar Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

アンドロゲン遮断療法の市場規模、シェア、成長分析、ADTタイプ別、適応症別、投与経路別、患者属性別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Androgen Deprivation Therapy Market Size, Share, and Growth Analysis, By Type of ADT (GnRH Analogues, Anti-androgens), By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

アンドロゲン遮断療法市場規模：ADTタイプ別& CAGR（2025-2032）

アンドロゲン遮断療法市場規模：適応症別& CAGR（2025-2032）

アンドロゲン遮断療法市場規模：投与経路別& CAGR（2025-2032）

アンドロゲン遮断療法市場規模：患者属性別& CAGR（2025-2032）

アンドロゲン遮断療法市場規模：流通チャネル別& CAGR（2025-2032）

アンドロゲン遮断療法市場規模：地域別& CAGR（2025-2032）